1. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Issue 9 (23rd June 2022) Authors: Vijayakumar, Archana; Okesli‐Armlovich, Ayse; Wang, Ting; Olson, Isabel; Seung, Minji; Kusam, Saritha; Hollenback, David; Mahadevan, Sangeetha; Marchand, Bruno; Toteva, Maria; Breckenridge, David G.; Trevaskis, James L.; Bates, Jamie Journal: Hepatology communications Issue: Volume 6:Issue 9(2022) Page Start: 2298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗